Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Current Leases (2020 - 2025)

Lexaria Bioscience's Current Leases history spans 6 years, with the latest figure at $31101.0 for Q4 2025.

  • For Q4 2025, Current Leases rose 7.94% year-over-year to $31101.0; the TTM value through Nov 2025 reached $31101.0, up 7.94%, while the annual FY2025 figure was $30417.0, 8.45% up from the prior year.
  • Current Leases for Q4 2025 was $31101.0 at Lexaria Bioscience, up from $30417.0 in the prior quarter.
  • Across five years, Current Leases topped out at $42587.0 in Q3 2022 and bottomed at $25554.0 in Q4 2023.
  • The 5-year median for Current Leases is $30417.0 (2025), against an average of $32977.8.
  • The largest annual shift saw Current Leases crashed 35.52% in 2023 before it grew 12.75% in 2024.
  • A 5-year view of Current Leases shows it stood at $39404.0 in 2021, then rose by 0.57% to $39629.0 in 2022, then plummeted by 35.52% to $25554.0 in 2023, then grew by 12.75% to $28812.0 in 2024, then rose by 7.94% to $31101.0 in 2025.
  • Per Business Quant, the three most recent readings for LEXX's Current Leases are $31101.0 (Q4 2025), $30417.0 (Q3 2025), and $29872.0 (Q2 2025).